JP2020535184A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535184A5 JP2020535184A5 JP2020517843A JP2020517843A JP2020535184A5 JP 2020535184 A5 JP2020535184 A5 JP 2020535184A5 JP 2020517843 A JP2020517843 A JP 2020517843A JP 2020517843 A JP2020517843 A JP 2020517843A JP 2020535184 A5 JP2020535184 A5 JP 2020535184A5
- Authority
- JP
- Japan
- Prior art keywords
- expression vector
- human subject
- hvegf
- use according
- pyroglutamylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023077454A JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564095P | 2017-09-27 | 2017-09-27 | |
| US62/564,095 | 2017-09-27 | ||
| US201762574657P | 2017-10-19 | 2017-10-19 | |
| US62/574,657 | 2017-10-19 | ||
| US201762579682P | 2017-10-31 | 2017-10-31 | |
| US62/579,682 | 2017-10-31 | ||
| US201862632812P | 2018-02-20 | 2018-02-20 | |
| US62/632,812 | 2018-02-20 | ||
| PCT/US2018/052855 WO2019067540A1 (en) | 2017-09-27 | 2018-09-26 | TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077454A Division JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020535184A JP2020535184A (ja) | 2020-12-03 |
| JP2020535184A5 true JP2020535184A5 (enExample) | 2021-09-30 |
| JP7685833B2 JP7685833B2 (ja) | 2025-05-30 |
Family
ID=65903176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517843A Active JP7685833B2 (ja) | 2017-09-27 | 2018-09-26 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
| JP2023077454A Pending JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077454A Pending JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200277364A1 (enExample) |
| EP (1) | EP3687464A4 (enExample) |
| JP (2) | JP7685833B2 (enExample) |
| KR (2) | KR20200060456A (enExample) |
| AU (2) | AU2018342094B2 (enExample) |
| CA (1) | CA3076905A1 (enExample) |
| IL (1) | IL273403A (enExample) |
| SG (1) | SG11202002396TA (enExample) |
| WO (1) | WO2019067540A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3721872B1 (en) | 2012-11-08 | 2025-01-22 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CA3010056A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| KR102574810B1 (ko) | 2016-04-15 | 2023-09-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 습성 연령 관련 황반 변성의 치료를 위한 조성물 |
| EA202091509A1 (ru) | 2017-12-19 | 2020-09-22 | Акуос, Инк. | Aav-опосредованная доставка терапевтических антител во внутреннее ухо |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| US20220133908A1 (en) * | 2019-02-08 | 2022-05-05 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
| EP3946467A1 (en) * | 2019-04-03 | 2022-02-09 | REGENXBIO Inc. | Gene therapy for eye pathologies |
| CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| CN114502197A (zh) | 2019-08-26 | 2022-05-13 | 再生生物股份有限公司 | 用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变 |
| JP2022552262A (ja) | 2019-10-07 | 2022-12-15 | リジェネックスバイオ インコーポレイテッド | アデノ随伴ウイルスベクター医薬組成物および方法 |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| US20230201371A1 (en) * | 2020-03-19 | 2023-06-29 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
| JP2023535632A (ja) | 2020-07-27 | 2023-08-18 | アンジャリウム バイオサイエンシズ エージー | Ｄｎａ分子の組成物、その作製方法、及びその使用方法 |
| EP4225381A1 (en) * | 2020-10-07 | 2023-08-16 | RegenxBio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| PH12023551518A1 (en) | 2020-12-01 | 2024-05-13 | Akouos Inc | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| BR112023015303A2 (pt) | 2021-02-01 | 2023-11-14 | Regenxbio Inc | Método para tratar doença cln2 devido a deficiência de tpp1 em um sujeito |
| MX2024003320A (es) * | 2021-09-18 | 2024-06-28 | Skyline Therapeutics Ltd | Virus adenoasociado para terapia génica de degeneración macular húmeda asociada con la edad. |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| IL319873A (en) | 2022-09-30 | 2025-05-01 | Regenxbio Inc | Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US20070202186A1 (en) * | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| CN102458471A (zh) * | 2009-05-28 | 2012-05-16 | 葛兰素集团有限公司 | 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合 |
| WO2010148223A2 (en) * | 2009-06-17 | 2010-12-23 | Facet Biotech Corporation | Anti-vegf antibodies and their uses |
| EP2559443A1 (en) * | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| KR20160086819A (ko) * | 2013-09-11 | 2016-07-20 | 뉴로테크 유에스에이, 인코포레이티드. | 캡슐화 세포 요법 카트리지 |
| US10064752B2 (en) * | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| CA3010862A1 (en) * | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
| KR102574810B1 (ko) * | 2016-04-15 | 2023-09-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 습성 연령 관련 황반 변성의 치료를 위한 조성물 |
| WO2017181021A1 (en) * | 2016-04-15 | 2017-10-19 | Regenxbio Inc. | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| US20210093734A1 (en) * | 2018-02-20 | 2021-04-01 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-realted macular degeneration |
| US20230201371A1 (en) * | 2020-03-19 | 2023-06-29 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
-
2018
- 2018-09-26 KR KR1020207011989A patent/KR20200060456A/ko not_active Ceased
- 2018-09-26 WO PCT/US2018/052855 patent/WO2019067540A1/en not_active Ceased
- 2018-09-26 EP EP18862872.1A patent/EP3687464A4/en active Pending
- 2018-09-26 CA CA3076905A patent/CA3076905A1/en active Pending
- 2018-09-26 SG SG11202002396TA patent/SG11202002396TA/en unknown
- 2018-09-26 KR KR1020257008245A patent/KR20250040754A/ko active Pending
- 2018-09-26 US US16/645,877 patent/US20200277364A1/en not_active Abandoned
- 2018-09-26 JP JP2020517843A patent/JP7685833B2/ja active Active
- 2018-09-26 AU AU2018342094A patent/AU2018342094B2/en active Active
-
2020
- 2020-03-18 IL IL273403A patent/IL273403A/en unknown
-
2023
- 2023-05-09 JP JP2023077454A patent/JP2023113641A/ja active Pending
- 2023-07-27 US US18/360,073 patent/US20240254214A1/en not_active Abandoned
-
2025
- 2025-02-26 US US19/064,049 patent/US20250320287A1/en active Pending
- 2025-05-02 AU AU2025203154A patent/AU2025203154A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535184A5 (enExample) | ||
| JP7544766B2 (ja) | 片頭痛の治療または予防法 | |
| US8758748B2 (en) | Anti-angiogenic therapy | |
| JP2010528047A5 (enExample) | ||
| AU2015204503B2 (en) | Novel vaccines against HPV and HPV-related diseases | |
| CN109071656A (zh) | 检查点调节物拮抗剂 | |
| US20220162296A1 (en) | Personalized treatment of ophthalmologic diseases | |
| HUE032654T2 (en) | scFv antibodies that cross the epithelial and / or endothelial layers | |
| TW201726741A (zh) | Ctla4結合劑 | |
| CN107635580A (zh) | 治疗眼病的方法 | |
| EP2021026A1 (en) | Use of il-i antibodies for treating ophthalmic disorders | |
| Touchard et al. | Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product | |
| KR102373289B1 (ko) | 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도 | |
| KR20220002972A (ko) | 변형 항 pd-l1 항체 및 신경변성 질환 치료 방법 및 용도 | |
| CN102958536A (zh) | 用抗-vegf疗法治疗血管化色素上皮脱离 | |
| WO2023070000A1 (en) | Methods of use and administration of encapsulated cells | |
| TW201806970A (zh) | 嵌合抗原受體、及其利用 | |
| JP2020518641A (ja) | Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法 | |
| JPWO2021041373A5 (enExample) | ||
| Matei et al. | What’s coming in therapies for diabetic retinopathy | |
| Park et al. | Clinical primer on Eylea HD: Review of the current data | |
| CN118791612A (zh) | 靶向cd26的抗原结合蛋白及其药物应用 | |
| CN118812720A (zh) | 靶向pdl1和cd3的双特异性抗体及其应用 | |
| Barakat et al. | Neovascular AMD: Where do we go from here? | |
| HK40065038A (en) | Personalized treatment of ophthalmologic diseases |